
Mold-Tek Packaging Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Volume growth guidance for FY '25 is around 15%, with a higher run rate of 17% needed in the remaining 9 months due to a moderate Q1 growth of 7.5%.
- Pharma segment is expected to grow significantly, contributing around INR15-20 crores in FY '25 with higher EBITDA, and potentially pushing turnover to INR50-60 crores by FY '26.
- Qpacks are growing rapidly, with expectations of 40-50% volume growth in the Food & FMCG segment.
- ABG segment capacity expansions (especially Cheyyar and Mahad plants) will add over 1,000 tons/month volume, supporting growth.
- Paints sector growth is expected around 8-10%, driven by ABG and other clients.
- Overall volumes grew by 7.5% in Q1 with a recent trend showing improvement, targeting continued growth from Q3 onward.
- The company aims to reach INR1,000 crores top line and INR100 crores PAT by FY '26/'27 largely driven by pharma and ABG expansions.
See what Mold-Tek Packaging management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The company has committed capex of around INR 55 to 58 crores for various expansions in FY '25.
- If volumes grow in pharma, additional growth investment might be required in the second half of the year.
- Overall capex for FY '25 is expected to be around INR 75 to 80 crores, compared to INR 140 crores last year.
- No direct mention or indication of new fundraising through debt or equity was made in the transcript.
- Focus seems to be on utilizing internal accruals and existing resources for capacity expansion and ramp-up.
See what Mold-Tek Packaging management said on order book — free account, 30 seconds.
Capex plans
Yes- Current committed capex for FY '25 is around INR 55 to 58 crores for various expansions.
- Additional growth investment in pharma may raise total capex to INR 75 to 80 crores by year-end.
- Capacity expansions include increasing ABG plants' capacity by 60% to 75% at Cheyyur and Mahad.
- Mahad plant will start supply from September/October, adding to volume growth.
- Pharma plant capacity may be enhanced with auxiliary machines within 3-4 months if needed.
- Capex in FY '25 is lower than last year's INR 140 crores.
- The company aims to double ABG capacities and expand pharmaceutical capacity to boost growth.
Track Mold-Tek Packaging — get its next earnings analysis in your feed
How does Mold-Tek Packaging rank vs peers in Industrial Products?
Pro featureHow does Mold-Tek Packaging rank in Industrial Products?
Compare Mold-Tek Packaging against every Industrial Products company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Mold-Tek Packaging's management said in earlier quarters
Others in Industrial Products this season
- KSB (Q2 FY27)
Revenue from operations (₹ Mn): . Key investor presentation takeaways from KSB Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
- Jindal Supreme (Q2 FY27)
For Q2 FY27, Revenue from Operations was ₹21,622 lakhs, a 36% year-on-year increase from ₹15,880 lakhs in Q2 FY26 (Page 6). Key investor presentation takeaways
- Supreme Engineering (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026: ₹578.74 lakh . Key results statement takeaways from Supreme Engineering Ltd's Q2 FY27 results
- Jindal Poly Film (Q2 FY27)
Year-on-Year Revenue Growth:** Approximately 26.5% increase [(73,806.55 . Key results statement takeaways from Jindal Poly Films Ltd's Q2 FY27 results statement